Intravascular OCT Catheter Technology Landscape 2026
Intravascular OCT Catheter Technology Landscape 2026
IV-OCT catheters deliver 10–20 µm cross-sectional vessel imaging — approximately 10 times finer than intravascular ultrasound. Patent activity from 2005–2026 maps four distinct architectural clusters spanning coronary, structural heart, neurovascular, and CTO indications.
IV-OCT Catheters: From Coronary Standard to Structural Heart Frontier
Intravascular optical coherence tomography uses near-infrared broadband light coupled through a rotating fiber inside a catheter sheath. As the fiber pulls back helically, backscattered light combines with a reference signal in an interferometer to generate real-time cross-sectional images of vessel walls at 10–20 µm resolution — enabling visualization of plaque morphology, stent apposition, and vascular microstructure during live interventions.
Within this dataset, IV-OCT systems cluster around four architectural themes: standalone swept-source OCT pullback catheters; hybrid OCT-IVUS dual-modality catheters; OCT systems co-registered with angiographic X-ray; and multimodal OCT-photoacoustic probes. Swept-source OCT using vertical cavity surface-emitting laser sources capable of 1 MHz axial scan rates has supplanted time-domain OCT as the preferred engine architecture, enabling faster pullback with denser sampling.
The resolution asymmetry between OCT (10–20 µm) and IVUS (approximately 100 µm) underpins the clinical rationale for hybrid systems: OCT delivers superior endoluminal surface detail, while IVUS provides deeper penetration to the external elastic membrane — genuinely complementary capabilities for complex lesion assessment. Commercial hybrid platforms from Conavi (Neovasc Tigris) and Terumo were confirmed by 2018, with active patent continuations persisting through 2022.
In retrieved records, Volcano Corporation (Philips) holds the largest identifiable OCT-IVUS hybrid patent family, with at least 5 active or granted US patents spanning 2009–2022. Siemens Healthcare GmbH accounts for 4 US co-registration patents (2007–2018), all carrying inactive legal status at retrieval. Canon U.S.A. entered the dataset with a 2026 pending US calibration patent, marking it as an emerging entrant in this dataset.
Patent Filing Phases and Technology Cluster Distribution
Patent activity in this dataset spans three identifiable evolutionary phases from 2005 to 2026, with distinct architectural clusters dominating each era. The transition from foundational fiber-optic designs to hybrid, co-registration, and multimodal architectures reflects both clinical demand and competitive differentiation pressure.
IV-OCT Patent Records by Technology Cluster — Dataset Snapshot
In this dataset, the hybrid OCT-IVUS cluster accounts for the highest number of retrieved records with at least 5 Volcano Corporation patents, followed by the OCT-to-X-ray co-registration cluster with 4 Siemens Healthcare patents, and standalone pullback catheters with records from Lumivascular, Canon, and others.
↗ Click bars to exploreIV-OCT Patent Filing Activity by Phase — Retrieved Records 2005–2026
In this dataset, filing activity across three phases shows the foundational period (2005–2009) establishing 3 core records, the development phase (2009–2018) producing the highest concentration of 9 records including Siemens co-registration and Volcano continuations, and the maturity phase (2019–2026) adding at least 8 records including Philips, Abbott, and Canon filings.
↗ Click bars to exploreKey Clinical Application Domains for IV-OCT Catheter Technology
IV-OCT catheter technology spans five distinct clinical application domains in this dataset, ranging from the mature interventional cardiology standard of care to nascent frontiers in structural heart, neurovascular, chronic total occlusion intervention, and oncologic surgical guidance.
Interventional Cardiology — Coronary PCI
The primary and most mature application domain, where OCT provides approximately 15 µm resolution — ten times higher than IVUS — enabling identification of thin-cap fibroatheroma, lipid pools, and stent strut coverage. Abbott’s Ultreon 1.0 software platform, referenced in a 2022 clinical outcome study comparing it to the earlier AptiVue generation, represents the current state of software-integrated OCT guidance for PCI. A 2020 study also documents saline-based contrast replacement for blood clearance, addressing contrast nephropathy risk during PCI.
Coronary InterventionStructural Heart — TAVR/TMVR Guidance
A recently active frontier documented by a 2025 WO patent from St. Jude Medical (Abbott), Cardiology Division, which claims a system integrating an OCT imaging probe within a transparent sheath co-deployed with a prosthetic heart valve for real-time intraprocedural guidance. This filing signals an active commercial push into TAVR/TMVR structural heart applications. Only this single commercial WO patent and early-stage academic literature address this application space in the dataset, indicating limited existing IP barriers compared to the coronary space.
Structural HeartNeurovascular — Cerebral Artery Imaging
A 2020 literature study describes an HF-OCT system approaching 10 µm resolution designed for safe deployment in tortuous cerebral vasculature, with an endoscopic probe acquiring volumetric microscopy of cerebral arteries. A 2019 study demonstrates HF-OCT use during intracranial aneurysm embolization, showing that neck coverage metrics from HF-OCT predict successful aneurysm occlusion outcomes. These studies represent early-stage clinical translation, with the 2020 study specifically noting the system’s suitability for the neurovascular anatomy.
NeurovascularChronic Total Occlusion Intervention
A 2025 WO patent by Koninklijke Philips N.V. explicitly addresses IV-OCT and IVUS use for imaging anatomical features and interventional devices associated with chronic total occlusions (CTOs), providing user guidance during CTO crossing and treatment. This represents an emerging indication requiring specialized catheter design for heavily calcified, occluded vessels. The filing reflects Philips’ expanded intravascular imaging portfolio following the Volcano acquisition, targeting an unmet clinical need where current imaging guidance is described as particularly challenging.
CTO InterventionKey Patent Assignees in IV-OCT Catheter Technology (Retrieved Records)
In this dataset, Volcano Corporation (Philips) holds the largest identifiable patent family with at least 5 active or granted US patents on OCT-IVUS hybrid catheters spanning 2009–2022, while Siemens Healthcare GmbH accounts for 4 US co-registration patents (2007–2018) all carrying inactive legal status at retrieval. Canon U.S.A. and Koninklijke Philips N.V. each contribute a single recent filing (2025–2026) in retrieved records, signaling continued commercial investment.
Top Assignees by Patent Record Count — IV-OCT Catheter Dataset (Dataset Snapshot)
↗ Click bars to exploreVolcano Corporation (Philips)
Volcano Corporation holds the largest identifiable patent family in this dataset with at least 5 active or granted US patents on the OCT-IVUS hybrid catheter concept, spanning from 2009 to 2022. The core patent family — “OCT-IVUS Catheter for Concurrent Luminal Imaging” — covers concurrent OCT and IVUS imaging of cardiac, peripheral, and neural vasculature in a single apparatus, with US continuations filed in 2019 and 2022. An additional WO filing (2015) claims catheter position tracking during OCT pullback using a radiolucent negative space volume, enabling improved co-localization with angiographic anatomy.
United StatesSiemens Healthcare GmbH
Siemens Healthcare GmbH is the dominant assignee in the OCT-to-X-ray co-registration niche in this dataset, with 4 US patents filed between 2007 and 2018. Key patents claim dual-pullback contrast-present/absent acquisition protocols to align OCT frames with X-ray angiogram landmarks (2018 US) and ECG-gated acquisition coordination between OCT imaging and X-ray fluoroscopy for cardiac-cycle-matched frame alignment (2013 US). All 4 Siemens co-registration patents in this dataset carry inactive legal status as of the retrieval date.
Germany — DEConvergent Innovation Signals in IV-OCT Catheter Technology (2023–2026)
The most recent filings (2023–2026) in this dataset signal five convergent directions: automatic AI-driven catheter calibration, OCT-guided structural heart interventions, CTO-specific imaging platforms, photonic miniaturization, and contrast-free acquisition. These directions collectively suggest competitive advantage is shifting from catheter hardware toward intelligent workflow integration.
Automatic Calibration and AI-Driven Catheter Intelligence
Canon U.S.A., Inc.’s 2026 pending US patent claims automated ex vivo and in vivo calibration, sheath detection, and tissue characterization integrated directly into the OCT catheter workflow. This signals a shift toward autonomous pre-procedure and intra-procedure calibration, reducing operator dependency and enabling more consistent image quality across operators and institutions. The patent covers cardio, gastrointestinal, and ophthalmic applications, indicating Canon’s intent to position this calibration platform broadly across endoscopic OCT use cases.
Photonic Integration and Miniaturization Toward Disposable Catheters
A 2022 literature review titled ‘Miniaturizing Optical Coherence Tomography’ identifies photonic integrated circuits (PICs) as an enabling technology for significant size and cost reduction of OCT catheter systems. This direction has direct implications for peripheral vascular and neurovascular deployment, where catheter profile and flexibility constraints are most acute. The review suggests PICs could enable disposable or ultra-low-profile IV-OCT catheters, potentially democratizing access to high-resolution intravascular imaging.
OCT vs. IVUS: Capability Trade-offs in Intravascular Imaging
Click any row to explore further.
| Dimension | Intravascular OCT | Intravascular Ultrasound (IVUS) |
|---|---|---|
| Axial Resolution | 10–20 µm (approximately 15 µm typical) | Approximately 100 µm |
| Relative Resolution Advantage | ~10× finer than IVUS | Baseline reference modality |
| Tissue Penetration Depth | Limited; superior endoluminal surface detail | Deeper penetration including external elastic membrane |
| Blood Clearance Requirement | Required (contrast agent or saline flushing for optical transparency) | Not required |
| Wavelength / Signal Type | Near-infrared light (~1300 nm), swept-source or time-domain | Acoustic/ultrasound |
| Primary Clinical Strengths | Thin-cap fibroatheroma, lipid pool identification, stent strut coverage assessment | Complex lesion depth assessment, external elastic membrane visualization |
| Hybrid Combination Rationale | Complementary with IVUS for complete vessel wall characterization | Complementary with OCT for complete vessel wall characterization |
| Commercial Hybrid Platform Examples | Conavi (Neovasc Tigris, combining OCT and IVUS), confirmed by 2018 | Conavi (Neovasc Tigris), Terumo (Novadaq), confirmed by 2018 |
Frequently Asked Questions — IV-OCT Catheter Technology
IV-OCT delivers 10–20 µm axial resolution — approximately 10 times finer than intravascular ultrasound (IVUS), which operates at approximately 100 µm resolution. OCT provides superior endoluminal surface detail, while IVUS offers deeper penetration into the vessel wall including the external elastic membrane.
In this dataset, IV-OCT catheter systems cluster around four architectural themes: (1) standalone swept-source or time-domain OCT pullback catheters; (2) hybrid OCT-IVUS dual-modality catheters combining optical and acoustic sensing in a single lumen; (3) OCT catheters co-registered with angiographic X-ray/fluoroscopy systems; and (4) multimodal probes pairing OCT with photoacoustic sensing.
In retrieved records, Volcano Corporation (Philips) holds the largest identifiable patent family with at least 5 active or granted US patents on OCT-IVUS hybrid catheters spanning 2009–2022. Siemens Healthcare GmbH holds 4 US co-registration patents (2007–2018), all with inactive legal status at retrieval. Canon U.S.A. and Koninklijke Philips N.V. each contribute one recent filing (2025–2026).
Emerging applications documented in this dataset include: structural heart interventions such as TAVR/TMVR (Abbott/St. Jude Medical, 2025 WO patent); neurovascular use in cerebral arteries and intracranial aneurysm embolization (2019–2020 literature); chronic total occlusion crossing (Koninklijke Philips N.V., 2025 WO); peripheral vascular; and OCT-guided intraoperative tumor margin assessment (University of Illinois, 2023 US patent).
IV-OCT requires blood clearance via contrast agent or saline flushing to achieve optical transparency. A 2020 clinical study systematically evaluated non-iodinated contrast media including saline as replacements for iodinated contrast, demonstrating technical feasibility. Eliminating iodinated contrast reduces contrast nephropathy risk and could enable broader OCT adoption in renal-impaired and high-contrast-risk patient populations.
A 2022 literature review identifies photonic integrated circuits (PICs) as an enabling technology for significant size and cost reduction of OCT catheter systems. This miniaturization direction has direct implications for peripheral vascular and neurovascular deployment where catheter profile constraints are most acute, and could enable disposable or ultra-low-profile IV-OCT catheters according to the review.
Data and insights on this page are based on a limited patent and literature dataset and are for reference only. Figures may not represent the complete technology landscape.